Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study

BACKGROUND AND AIMS: Pirfenidone (PFD), an oral antifibrotic drug, has been authorized by the EMA and FDA for treatment of idiopathic pulmonary fibrosis. Few studies have addressed its use in advanced liver fibrosis (ALF). We evaluated a prolonged-release formulation (PR-PFD) plus standard of care o...

Descripción completa

Detalles Bibliográficos
Autores principales: Poo, Jorge Luis, Torre, Aldo, Aguilar-Ramírez, Juan Ramón, Cruz, Mauricio, Mejía-Cuán, Luis, Cerda, Eira, Velázquez, Alfredo, Patiño, Angélica, Ramírez-Castillo, Carlos, Cisneros, Laura, Bosques-Padilla, Francisco, Hernández, Larissa, Gasca, Frida, Flores-Murrieta, Francisco, Treviño, Samuel, Tapia, Graciela, Armendariz-Borunda, Juan, Muñoz-Espinosa, Linda E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561536/
https://www.ncbi.nlm.nih.gov/pubmed/32813194
http://dx.doi.org/10.1007/s12072-020-10069-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561536/
https://www.ncbi.nlm.nih.gov/pubmed/32813194
http://dx.doi.org/10.1007/s12072-020-10069-3

Ejemplares similares